Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program

  • Hoth Therapeutics Inc HOTH has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model.
  • HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer's disease.
  • The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing. 
  • All behavioral tests performed after >5 weeks of treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle-treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild-type (non-AD) animals. 
  • Related: Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury.
  • Other behavioral assessments performed at earlier treatment periods (less than five weeks) with HT-ALZ did not significantly improve compared to vehicle-treated animals.
  • However, they were trending positively toward improvement, suggesting a time-dependent improvement after initiation of HT-ALZ treatment. 
  • These other behavioral assessments are repeated after longer HT-ALZ dosing periods (eg, six weeks).
  • Price Action: HOTH shares are up 28.9% at $0.52 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!